Related references
Note: Only part of the references are listed.A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer
Hatem Soliman et al.
CLINICAL CANCER RESEARCH (2021)
Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients
A. Algazi et al.
ANNALS OF ONCOLOGY (2020)
A Small Number of HER2 Redirected CAR T Cells Significantly Improves Immune Response of Adoptively Transferred Mouse Lymphocytes against Human Breast Cancer Xenografts
Gabor Toth et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity
Matthew Kraman et al.
CLINICAL CANCER RESEARCH (2020)
Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
Wenting Zhang et al.
FRONTIERS IN IMMUNOLOGY (2020)
Role of Immunotherapy in Triple-Negative Breast Cancer
Tanya E. Keenan et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Addition of dendritic cell vaccines to neoadjuvant chemotherapy in HER2 negative breast cancer patients
A. Urrizola et al.
ANNALS OF ONCOLOGY (2020)
Phase 2, open-label study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation in combination with intravenous pembrolizumab therapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (mTNBC) (KEYNOTE-890/OMS-I141)
Melinda L. Telli et al.
CANCER RESEARCH (2020)
Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients
Lawrence G. Lum et al.
ONCOIMMUNOLOGY (2020)
Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers
V. Chung et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants
M. Messaoudene et al.
ANNALS OF ONCOLOGY (2019)
Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial
Elizabeth A. Mittendorf et al.
CLINICAL CANCER RESEARCH (2019)
Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naive to anti-PD-1 therapy.
Mohammed M. Milhem et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).
Hoyoung M. Maeng et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase II clinical trial using anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) for HER2-negative (0-2+) metastatic breast cancer.
Lawrence G. Lum et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers
Arielle Oglesby et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2019)
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III- IV melanoma
Robert H. Andtbacka et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies
Sandra M. M. Irenaeus et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis
Li-Chung Tsao et al.
JCI INSIGHT (2019)
Catumaxomab with Activated T-cells Efficiently Lyses Chemoresistant EpCAM-positive Triple-negative Breast Cancer Cell Lines
Makoto Kubo et al.
ANTICANCER RESEARCH (2018)
Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia
Vanessa Buatois et al.
MOLECULAR CANCER THERAPEUTICS (2018)
A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer
Hatem Soliman et al.
Oncotarget (2018)
Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy
Yismeilin R. Feliz-Mosquea et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first- line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Final results from the run-in phase of a placebo-controlled randomized phase II
Francois P. Duhoux et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naive to anti-PD-1 therapy
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Ranjana Advani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
Praveen K. Bommareddy et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2017)
Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid)
David A. Canton et al.
IMMUNOTHERAPY (2017)
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Julia Tchou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
LAG-3+tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+tumors
S. Burugu et al.
ANNALS OF ONCOLOGY (2017)
Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy
Frederick J. Kohlhapp et al.
CLINICAL CANCER RESEARCH (2016)
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence
E. A. Mittendorf et al.
ANNALS OF ONCOLOGY (2016)
Coinhibitory Pathways in Immunotherapy for Cancer
Susanne H. Baumeister et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 34 (2016)
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors
Steven A. Limentani et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer
Giuseppe Curigliano et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
Avery D. Posey et al.
IMMUNITY (2016)
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence
Elizabeth A. Mittendorf et al.
ONCOTARGET (2016)
Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer
Adam R. Root et al.
ANTIBODIES (2016)
A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma
A. K. Nowak et al.
ANNALS OF ONCOLOGY (2015)
Generation and characterization of a bispecific diabody targeting both EPH receptor A10 and CD3
Haruhiko Kamada et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma
Douglas B. Johnson et al.
IMMUNOTHERAPY (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer A Randomized Clinical Trial
Christopher R. Heery et al.
JAMA ONCOLOGY (2015)
4-1 BB agonists: multi-potent potentiators of tumor immunity
Todd Bartkowiak et al.
FRONTIERS IN ONCOLOGY (2015)
OX40 agonists anc combination immunotherapy: putting the pedal to the metal
Stefanie N. Linch et al.
FRONTIERS IN ONCOLOGY (2015)
New insights into IL-12-mediated tumor suppression
S. Tugues et al.
CELL DEATH AND DIFFERENTIATION (2015)
A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer
Gang Chen et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cells
Venkataswarup Tiriveedhi et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2013)
Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1
Stamatis Vassilaros et al.
IMMUNOTHERAPY (2013)
A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma
Andrea Wang-Gillam et al.
INVESTIGATIONAL NEW DRUGS (2013)
Intralesional Injection of Rose Bengal Induces a Systemic Tumor-Specific Immune Response in Murine Models of Melanoma and Breast Cancer
Paul Toomey et al.
PLOS ONE (2013)
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
Robert H. Vonderheide et al.
ONCOIMMUNOLOGY (2013)
Electrochemotherapy for large cutaneous recurrence of breast cancer: A phase II clinical trial
Louise Wichmann Matthiessen et al.
ACTA ONCOLOGICA (2012)
HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ
Anupama Sharma et al.
CANCER (2012)
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Stephen B. Willingham et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Electrochemotherapy of cutaneous metastastes from breast cancer in elderly patients: a preliminary report
Raffaella Benevento et al.
BMC SURGERY (2012)
A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer
Mahsa Mohebtash et al.
CLINICAL CANCER RESEARCH (2011)
Analysis of CD40 expression in breast cancer and its relation to clinicopathological characteristics.
Z. Slobodova et al.
NEOPLASMA (2011)
Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer
David Miles et al.
ONCOLOGIST (2011)
A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study
Ursula Wiedermann et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Results of Two Phase I Clinical Trials of MVA-BN®-HER2 in HER-2 Overexpressing Metastatic Breast Cancer Patients.
A. Guardino et al.
CANCER RESEARCH (2010)
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
Chrystelle Brignone et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia
Richard R. Furman et al.
LEUKEMIA & LYMPHOMA (2010)
Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
Leisha A. Emens et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Toll-Like Receptor-9 Expression Is Inversely Correlated with Estrogen Receptor Status in Breast Cancer
Arja Jukkola-Vuorinen et al.
JOURNAL OF INNATE IMMUNITY (2009)
Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients:: US military cancer institute clinical trials group study I-01 and I-02
George E. Peoples et al.
CLINICAL CANCER RESEARCH (2008)
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma
James L. Gulley et al.
CLINICAL CANCER RESEARCH (2008)
Sipuleucel-T for the treatment of prostate cancer
Andrea L. Harzstark et al.
DRUGS OF TODAY (2008)
Telomerase-specific T-Cell immunity in breast cancer: Effect of vaccination on tumor immunosurveillance
Susan M. Domchek et al.
CANCER RESEARCH (2007)
Prospect of targeting the CD40 pathway for cancer therapy
Robert H. Vonderheide
CLINICAL CANCER RESEARCH (2007)
Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation
Cristiana Guiducci et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Enhanced phagocytosis of CD47-deficient red blood cells by splenic macrophages requires SHPS-1
T Ishikawa-Sekigami et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer
Philipp Kiewe et al.
CLINICAL CANCER RESEARCH (2006)
CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A
PP Manna et al.
CANCER RESEARCH (2004)
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression
Y Oka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients
ML Disis et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2004)
EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy
WA Osta et al.
CANCER RESEARCH (2004)
Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses
D Avigan et al.
CLINICAL CANCER RESEARCH (2004)
Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study
IM Svane et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Electrochemotherapy with cisplatin of cutaneous tumor lesions in breast cancer
M Rebersek et al.
ANTI-CANCER DRUGS (2004)
Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: Clinical and immunological results
A Dols et al.
HUMAN GENE THERAPY (2003)
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties
BL Liu et al.
GENE THERAPY (2003)
Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA
MA Morse et al.
CANCER INVESTIGATION (2003)
Immunization of metastatic breast cancer patients with a fully synthetic globe H conjugate: A phase I trial
T Gilewski et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
CD40 ligation for immunotherapy of solid tumours
SM Todryk et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2001)
Immunization with a HER-2/neu helper peptide generates HER-2/neu CD8 T-cell immunity in cancer patients
KL Knutson et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Share Paper
